KW-2871

· Kyowa Kirin, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KW-2871, covering 2024-05-03 to 2024-05-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma [Phase 1, Phase 2]